Madrigal is pioneering a new frontier in metabolic care by focusing on the liver, an organ often overlooked despite its deep connection to diabetes. Their first-of-its-kind medication, resmetirom (Rezdiffra), is a once-daily pill that targets the liver’s thyroid hormone receptors to clear out fat and reduce inflammation. This matters because it is the first FDA-approved treatment for MASH (formerly NASH), a severe form of liver disease that affects many people with type 2 diabetes and can lead to irreversible scarring (fibrosis). By reactivating healthy liver metabolism, Madrigal’s therapy helps stabilize Time in Range (TIR) and reduces the long-term risk of liver failure and cardiovascular events, providing a critical missing piece in the management of total-body metabolic health.